Assembly Biosciences, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection. Its product candidates include Vebicorvir to treat patients with chronic HBV infection; ABI-H2158, which is in Phase II clinical study for chronic HBV infection; ABI-H3733 that has completed Phase Ia clinical study for the treatment of HBV. The company has collaboration agreements with Allergan Pharmaceuticals International Limited; BeiGene, Ltd.; and Arbutus Biopharma Corporation, as well as strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was founded in 2005 and is headquartered in South San Francisco, California.
IPO Year: 2010
Exchange: NASDAQ
Website: assemblybio.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/24/2025 | $38.00 | Mkt Outperform | Citizens JMP |
| 8/18/2025 | $50.00 | Buy | H.C. Wainwright |
| 3/25/2025 | $31.00 | Buy | Guggenheim |
| 9/20/2024 | $2.00 → $35.00 | Hold → Buy | Jefferies |
| 9/13/2021 | $3.50 | Neutral | HC Wainwright & Co. |
| 9/2/2021 | Outperform → Market Perform | William Blair |
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)
4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)
4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)
4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)
4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)
4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)
4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)
4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)
4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Citizens JMP initiated coverage of Assembly Biosciences with a rating of Mkt Outperform and set a new price target of $38.00
H.C. Wainwright resumed coverage of Assembly Biosciences with a rating of Buy and set a new price target of $50.00
Guggenheim initiated coverage of Assembly Biosciences with a rating of Buy and set a new price target of $31.00
Jefferies upgraded Assembly Biosciences from Hold to Buy and set a new price target of $35.00 from $2.00 previously
HC Wainwright & Co. initiated coverage of Assembly Biosciences with a rating of Neutral and set a new price target of $3.50
William Blair downgraded Assembly Biosciences from Outperform to Market Perform
SVB Leerink reiterated coverage of Assembly Biosciences with a rating of Market Perform and set a new price target of $7.00 from $8.00 previously
SVB Leerink downgraded Assembly Biosciences from Outperform to Mkt Perform
SVB Leerink downgraded Assembly Biosciences from Outperform to Market Perform and set a new price target of $8.00 from $9.00 previously
Truist reiterated coverage of Assembly Biosciences with a rating of and set a new price target of $15.00 from $45.00 previously
Fastest customizable press release news feed in the world
SOUTH SAN FRANCISCO, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today announced senior management will participate in fireside chats at two upcoming investor conferences: Jefferies 2026 Global Healthcare ConferenceDate: June 3, 2026Time: 4:20 p.m. ET Goldman Sachs 47th Annual Global Healthcare ConferenceDate: June 8, 2026Time: 8:40 a.m. ET To register for either webcast, please visit the Events and Presentations section of Assembly Bio's website at: https://investor.assemblybio.com/events-presentations. A replay will be accessible following each
SOUTH SAN FRANCISCO, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today announced the closing of its previously announced underwritten registered offering of 3,924,624 shares of its common stock at an offering price per share of common stock of $26.50, which includes the exercise in full by the underwriters of their option to purchase 566,040 additional shares of common stock. In addition, and in lieu of common stock, Assembly Bio sold to a certain existing investor pre-funded warrants to purchase up to an aggregate of 415,000 shares of common stock a
SOUTH SAN FRANCISCO, Calif., May 22, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today announced the pricing of an underwritten, registered offering (the offering) of an aggregate of 3,358,602 shares of common stock at an offering price per share of common stock of $26.50, and, to certain investors in lieu of common stock, pre-funded warrants to purchase up to 415,000 shares of common stock at an offering price per pre-funded warrant of $26.499, which represents the per share offering price of the common stock less the $0.001 exercise price per share for each pre-fu
– Phase 2 study in cholestatic liver diseases, focused on PBC and PSC, anticipated to initiate in Q1 2027 –– Builds on completed Phase 1a study and ongoing development in HDV – SOUTH SAN FRANCISCO, Calif., May 22, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced plans to expand the clinical development of ABI-6250, its oral entry inhibitor candidate for chronic hepatitis delta virus (HDV) infection, into primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC), broadening the program into cholestatic liver diseases. "We are excited to expand the
SOUTH SAN FRANCISCO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced topline clinical data on ABI-6250, an investigational oral hepatitis D virus (HDV) entry inhibitor, will be presented in a poster presentation at the European Association for the Study of the Liver (EASL) Congress taking place May 27-30, 2026, in Barcelona, Spain. "We are pleased to present additional Phase 1a data on ABI-6250 at EASL," said Anuj Gaggar, MD, PhD, chief medical officer of Assembly Bio. "As the only oral entry inhibitor currently in clinical development for chronic
SOUTH SAN FRANCISCO, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced that Anuj Gaggar, MD, PhD, chief medical officer, will present during the Bank of America Securities 2026 Global Health Care Conference at 4:35 p.m. Pacific Time on May 13, 2026. A live webcast will be available on the Events and Presentations section of Assembly Bio's website, and a replay will be accessible following the event. To register for the live webcast and replay, please visit: https://investor.assemblybio.com/events-presentations. About Assembly Biosciences Assembly B
– Completed Phase 1b studies for ABI-5366 and ABI-1179, helicase-primase inhibitors for recurrent genital herpes – – Completed chronic toxicology studies for ABI-6250, an oral small-molecule entry inhibitor candidate for chronic hepatitis delta virus; Phase 2 initiation anticipated Q4 2026 – SOUTH SAN FRANCISCO, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today reported financial results for the first quarter ended March 31, 2026, and recent highlights. "The first quarter reflected steady progress across our portfolio as we continue advancing our discovery
– Successfully licensed helicase-primase inhibitor program for recurrent genital herpes to Gilead, including candidates ABI-5366 and ABI-1179, following positive Phase 1b interim data; development plan anticipated by mid-2026 – – Phase 2 initiation for ABI-6250, an oral small-molecule entry inhibitor candidate for chronic hepatitis delta virus, anticipated by end of 2026 – SOUTH SAN FRANCISCO, Calif., March 19, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today reported financial results for the year ended December 31, 2025, and recent highlights. "2025 was a pivotal year f
– Weekly Oral Helicase-Primase Inhibitor Programs' Early Data Potentially Supportive of First New Treatment for Recurrent Genital Herpes in 25 Years – Gilead Sciences, Inc. (NASDAQ:GILD) and Assembly Biosciences, Inc. (NASDAQ:ASMB), today announced Gilead has exercised its combined option to exclusively license Assembly Bio's herpes simplex virus (HSV) helicase-primase inhibitor programs, including long-acting investigational candidates ABI-1179 and ABI-5366 for recurrent genital herpes. These represent the first programs Gilead will advance under the ongoing Assembly Bio R&D collaboration, reinforcing the companies' commitment to building a novel antiviral pipeline and driving long-term
– 98% reduction in HSV-2 shedding rate, >99% reduction in high viral load shedding rate and 91% reduction in virologically confirmed genital lesion rate observed in 50 mg weekly oral dose of ABI-1179, exceeding expectations for the study – – 76% reduction in HSV-2 shedding rate, 81% reduction in high viral load shedding rate and 88% reduction in virologically confirmed genital lesion rate observed in proof-of-concept test of monthly oral dose of ABI-5366 – – Company to hold conference call today at 6 p.m. ET – SOUTH SAN FRANCISCO, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing innovative therapeutics targeting seri
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)
4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)
4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)
4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)
4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)
4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)
4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)
4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)
4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)
4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)
8-K - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Filer)
SCHEDULE 13D/A - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Subject)
8-K - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Filer)
424B5 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Filer)
424B5 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Filer)
8-K - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Filer)
10-Q - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Filer)
8-K - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Filer)
DEFA14A - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Filer)
DEF 14A - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Filer)
Live Leadership Updates
-- Dr. Gaggar is an experienced industry executive with substantial infectious disease expertise and proven record of successfully leading early- and clinical-stage antiviral programs -- SOUTH SAN FRANCISCO, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced that Anuj Gaggar, MD, PhD, has joined the company as chief medical officer. Dr. Gaggar is an infectious disease specialist and seasoned executive whose experience has focused on the development of new therapies in viral diseases including chronic hepatitis B virus (HBV), hepatitis C vi
−ABI-5366 Demonstrates Favorable Profile for a Long-Acting Therapeutic in Preclinical Studies −IND-Enabling Studies Initiating for 5366, Supporting Anticipated IND/CTA Filing in 1H2024 SOUTH SAN FRANCISCO, Calif., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced the selection of development candidate ABI-5366 (5366) to progress to IND-enabling studies for its long-acting herpes simplex virus type 2 (HSV-2) helicase inhibitor program. 5366 is the first development candidate from Assembly Bio's discovery pipeline nominated for adv
Carver Biosciences, Inc., a biotech company focused on the development of CRISPR/Cas13 antivirals, today announced the formation of its Scientific Advisory Board (SAB). Cameron Myhrvold Ph.D., co-founder of Carver will serve as the chairman of the SAB. Additional appointments include Uri Lopatin, M.D., Olivia Merkel, Ph.D., and Neville Sanjana, Ph.D. "I am thrilled to have Dr. Lopatin, Dr. Merkel and Dr. Sanjana join our advisory board," said Dr. Walter Strapps, co-founder and CEO of Carver. "Along with Dr. Myhrvold, these scientific leaders will help us shape our pipeline and advance our programs into the clinic." Uri Lopatin, M.D. Dr. Lopatin is a serial biotech entrepreneur who founde
In initial ABI-H3733 cohort of 50 mg in 28-day Phase 1b study, six of eight HBV patients on treatment reached lower limit of quantification for HBV DNA by day 21 and patients showed a mean reduction of 3.1 logs in plasma HBV DNAInitial ABI-4334 Phase 1a single-dose 30 mg cohort demonstrated pharmacokinetic profile supportive of once-daily oral dosing and provides early indication that ABI-4334's very high potency seen preclinically can be accessed clinicallyNo serious adverse events or significant laboratory abnormalities including alanine aminotransferase (ALT) elevation were observed in either study Given potent antiviral activity in the initial 50 mg cohort, second 25 mg cohort ongoing in
Healthy volunteer study will inform development of 4334 for treatment of hepatitis B virus SOUTH SAN FRANCISCO, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company developing innovative, investigational therapeutics targeting hepatitis B virus (HBV) and other viral diseases, today announced that the first subject has been dosed in the Phase 1a trial of its investigational core inhibitor ABI-4334 (4334). 4334 is an investigational next-generation core inhibitor that is optimized for significantly increased potency against covalently closed circular DNA (cccDNA) formation and new virus production versus first-generation
Data demonstrating nanomolar potency of core inhibitor ABI-4334 to disrupt the hepatitis B virus (HBV) life cycle at multiple points supports advancement into clinical studies First data presented on preclinical characterization of potent, orally bioavailable viral entry inhibitors for HBV and hepatitis D virus (HDV) First data presented on novel series of orally bioavailable small molecule interferon-a receptor (IFNAR) agonists designed to inhibit HBV and engage the immune system with potential to offer improved tolerability SOUTH SAN FRANCISCO, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company developing innovati
SOUTH SAN FRANCISCO, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company developing innovative, investigational therapeutics targeting hepatitis B virus (HBV) and other viral diseases, today announced that John G. McHutchison, AO, MD, chief executive officer (CEO), will retire as CEO at the end of 2022. Dr. McHutchison will continue to serve on Assembly Bio's Board of Directors, including assuming the role of chairman of the Science and Technology Committee. Assembly Bio's Board of Directors has unanimously elected Jason A. Okazaki, the company's current president and chief operating officer (COO), as chief executive of
This live feed shows all institutional transactions in real time.
SC 13G - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Subject)
SC 13D/A - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Subject)
SC 13D/A - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Subject)
SC 13D/A - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Subject)
SC 13D/A - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Subject)
SC 13D - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Subject)
SC 13D - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Subject)
SC 13G/A - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Subject)
SC 13G/A - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Subject)
SC 13G/A - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Subject)
Live finance-specific insights
– 98% reduction in HSV-2 shedding rate, >99% reduction in high viral load shedding rate and 91% reduction in virologically confirmed genital lesion rate observed in 50 mg weekly oral dose of ABI-1179, exceeding expectations for the study – – 76% reduction in HSV-2 shedding rate, 81% reduction in high viral load shedding rate and 88% reduction in virologically confirmed genital lesion rate observed in proof-of-concept test of monthly oral dose of ABI-5366 – – Company to hold conference call today at 6 p.m. ET – SOUTH SAN FRANCISCO, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing innovative therapeutics targeting seri